Source: International Congress 2014 – Sarcoidosis
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Martusewicz-Boros, P. Boros, E. Wiatr, K. Roszkowski-Sliz (Warsaw, Poland). How many patients require corticosteroid treatment in sarcoidosis? – Preliminary study. Eur Respir J 2014; 44: Suppl. 58, 464

Member's Comments

No comment yet.

Related content which might interest you: Is pulmonary sarcoidosis more severe in children? A multicentric retrospective study Source: International Congress 2014 – Sarcoidosis Year: 2014 Diagnosis of cardiac sarcoidosis: A crossectional study in 327 consecutive patients Source: International Congress 2014 – Sarcoidosis Year: 2014 Comorbidities associated with sarcoidosis – Results from long-term observational study Source: International Congress 2014 – Sarcoidosis Year: 2014 Treatment of IPF with inhaled IFN-gamma; planning for a clinical trial Source: International Congress 2014 – ILDs 3 Year: 2014 Atypical variants of clinical course of sarcoidosis Source: International Congress 2014 – ILDs 6 Year: 2014 Clinical profile and early follow-up of patients receiving pirfenidone in the PIONEER observational study Source: International Congress 2014 – ILDs 6 Year: 2014 Benefit of steroid-free treatment compared to standard therapy (ST) in pulmonary sarcoidosis Source: International Congress 2014 – ILDs 5 Year: 2014 Predictors of cardiovascular events in newly diagnosed patients with sarcoidosis Source: International Congress 2014 – Sarcoidosis Year: 2014 Long-term safety of pirfenidone in RECAP, an open-label extension study in patients with idiopathic pulmonary fibrosis, interim results Source: International Congress 2014 – Clinical trials in IPF Year: 2014 Methotrexate (MTX) as a single agent for treating chronic, progressive sarcoidosis Source: International Congress 2014 – Sarcoidosis Year: 2014 Acute exacerbation of idiopathic pulmonary fibrosis: Analysis in a post-marketing surveillance of pirfenidone Source: International Congress 2014 – Clinical trials in IPF Year: 2014 Intraindividual response to treatment with pirfenidone in two independent European IPF cohorts Source: International Congress 2014 – ILDs 2 Year: 2014 Reduction in disease progression with nintedanib in the INPULSIS™ trials Source: International Congress 2014 – Clinical trials in IPF Year: 2014 Sensitivity analyses from the INPULSIS™ trials of nintedanib Source: International Congress 2014 – Clinical trials in IPF Year: 2014 Pirfenidone post-authorization safety registry (PASSPORT) – Interim analysis of IPF treatment Source: International Congress 2014 – Clinical trials in IPF Year: 2014 Pulmonary function changes during treatment with rituximab in patients with rheumatoid arthritis Source: International Congress 2014 – ILDs: pathogenesis and clinical features Year: 2014 LATE-BREAKING ABSTRACT: Current management of patients with idiopathic pulmonary fibrosis in clinical practice: INSIGHTS-IPF registry Source: International Congress 2014 – Clinical trials in IPF Year: 2014 Extrapulmonary involvement in sarcoidosis patients Source: International Congress 2014 – ILDs 4 Year: 2014 Steroid treatment effect in pulmonary sarcoidosis (STEPS study) Source: International Congress 2015 – Sarcoidosis: clinical Year: 2015 Clinical features and prognosis of 108 patients with lymphangioleiomyomatosis Source: International Congress 2014 – ILDs: diagnostic and prognostic investigations Year: 2014